CA2163450A1 - Facteurs embryotoxiques - Google Patents

Facteurs embryotoxiques

Info

Publication number
CA2163450A1
CA2163450A1 CA002163450A CA2163450A CA2163450A1 CA 2163450 A1 CA2163450 A1 CA 2163450A1 CA 002163450 A CA002163450 A CA 002163450A CA 2163450 A CA2163450 A CA 2163450A CA 2163450 A1 CA2163450 A1 CA 2163450A1
Authority
CA
Canada
Prior art keywords
embryotoxic
factor
concentration
sample
reproductive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002163450A
Other languages
English (en)
Inventor
Joseph A. Hill
Deborah J. Anderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2163450A1 publication Critical patent/CA2163450A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/52—Sperm; Prostate; Seminal fluid; Leydig cells of testes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)

Abstract

L'invention concerne des procédés et des compositions de diagnostic et de traitement d'anomalies reproductives immunologiques chez le mammifère. Lesdits procédés consistent à déterminer la présence d'une concentration élevée d'un facteur embryotoxique extracellulaire dans un échantillon. Ledit échantillon contient des leucocytes ou des produits de sécrétion de leucocytes. L'invention porte également sur le matériel permettant de déterminer la concentration desdits facteurs embryotoxiques.
CA002163450A 1993-05-21 1994-05-20 Facteurs embryotoxiques Abandoned CA2163450A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6590393A 1993-05-21 1993-05-21
US08/065,903 1993-05-21

Publications (1)

Publication Number Publication Date
CA2163450A1 true CA2163450A1 (fr) 1994-12-08

Family

ID=22065922

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002163450A Abandoned CA2163450A1 (fr) 1993-05-21 1994-05-20 Facteurs embryotoxiques

Country Status (4)

Country Link
EP (1) EP0700523A1 (fr)
AU (1) AU6954494A (fr)
CA (1) CA2163450A1 (fr)
WO (1) WO1994028425A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001292621A1 (en) * 2000-09-12 2002-03-26 Dana-Farber Cancer Institute Inc. Variants of il-1 beta gene and cd46 gene for diagnosing unexplained recurrent pregnancy loss
WO2003045361A1 (fr) * 2001-11-30 2003-06-05 Solvay Pharmaceuticals Gmbh Prevention de fausse couche faisant appel a des composes gestagenes non endogenes d'immunomodulation
WO2012125641A1 (fr) 2011-03-17 2012-09-20 Cedars-Sinai Medical Center Biomarqueur de diagnostic pour prédire un risque d'accouchement prématuré
ITMI20130916A1 (it) * 2013-06-04 2014-12-05 Gexnano S R L Metodo di rilevazione di sostanze chimiche in campioni di materiale prelevabili da un soggetto, in particolare di rilevazione di fattori embriotossici

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8801383A1 (es) * 1985-06-27 1988-01-01 Biogen Nv Un procedimiento para purificar uromodulina a partir de orina cruda
AU638207B2 (en) * 1988-03-18 1993-06-24 Institut National De La Recherche Agronomique (Inra) Isoforms of trophoblastine
US4997646A (en) * 1989-02-23 1991-03-05 University Of Florida Research Foundation, Inc. Use of interferons of the alpha family to enhance fertility in mammals
EP0642667B1 (fr) * 1991-11-04 2001-01-10 Adeza Biomedical Corporation Procede de depistage pour l'identification de femmes presentant un risque accru d'accouchement avant terme
JPH05209882A (ja) * 1992-01-31 1993-08-20 Tosoh Corp 流早産の診断方法

Also Published As

Publication number Publication date
WO1994028425A1 (fr) 1994-12-08
AU6954494A (en) 1994-12-20
EP0700523A1 (fr) 1996-03-13

Similar Documents

Publication Publication Date Title
Sheth et al. Prediction of successful embryo implantation by measuring interleukin-1-alpha and immunosuppressive factor (s) in preimplantation embryo culture fluid
Yamada et al. Cell-mediated immunity to trophoblast antigens in women with recurrent spontaneous abortion
Katz et al. Recurrent miscarriage
Margalioth et al. Correlation between the zona-free hamster egg sperm penetration assay and human in vitro fertilization
EP1927362A2 (fr) Intégrine alpha/bêta 3 en tant que prédicateur d'endométrioses
US7723289B2 (en) PIF tetrapeptides
Coulam Immunotherapy for recurrent spontaneous abortion
Hornung et al. Histocompatibility leukocyte antigen-G is not expressed by endometriosis or endometrial tissue
CA2163450A1 (fr) Facteurs embryotoxiques
US20090081225A1 (en) PIF peptides biologic activities, site of action, and the antibody to detect PIF
NZ547139A (en) Use of preimplantation factor peptides to treat intolerence to embryo implantation
McShane et al. Cellular immunity to sperm in infertile women
Hjort et al. Anti-sperm antibodies and immune subfertility
Radojčić et al. Anticardiolipin antibodies in women with unexplained infertility
Ohashi et al. Evaluation of acrosomal status using MH61-beads test and its clinical application
Tedesco et al. Prevalence and biological effects of anti‐trophoblast and anti‐endothelial cell antibodies in patients with recurrent spontaneous abortions
Scott et al. Potential alloimmune factors and immunotherapy in recurrent miscarriage
Taşdemir et al. Sperm immobilization antibodies in infertile male sera decrease the acrosome reaction: a possible mechanism for immunologic infertility
MacLaren et al. Maternal serum reactivity to species-specific antigens in sheep-goat interspecific pregnancy
Chandra et al. Post-translational modifications in glycosylation status during epididymal passage and significance in fertility of a 33 kDa glycoprotein (MEF3) of rhesus monkey (Macaca mulatta)
US11422138B2 (en) Detection and treatment of pregnancy complications comprising determining sialyl Lewis antigens and administering hCG
Zhao et al. Maternal and Fetal CD4+ CD25+ CD127low/-Regulatory T Cells in Pregnancies with Gestational Diabetes, Preeclampsia, and Premature Rupture of Membranes
ALLEN et al. Immunosuppression in the mouse by porcine uterine secretory protein
Ekroth The relationship between gamete compatibility and immune system
Hamonic Evaluating the innate immune response of the porcine uterus to vaccine adjuvants for the development of an intrauterine vaccine

Legal Events

Date Code Title Description
FZDE Dead